PainReform Ltd. (PRFX)
3.46
-0.01 (-0.29%)
At close: Feb 20, 2025, 3:59 PM
3.45
-0.14%
After-hours: Feb 20, 2025, 06:48 PM EST
undefined% (undefined)
| Bid | 3.45 |
| Market Cap | 3.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -147.36 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.48 |
| Volume | 113,466 |
| Avg. Volume (20D) | 3,644,062 |
| Open | 3.41 |
| Previous Close | 3.47 |
| Day's Range | 3.26 - 3.53 |
| 52-Week Range | 0.43 - 16.63 |
| Beta | undefined |
About PRFX
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the tre...
Sector Healthcare
IPO Date Sep 1, 2020
Employees 7
Stock Exchange NASDAQ
Ticker Symbol PRFX
Website https://www.painreform.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PRFX stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 1289.29% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 0.00%
2 days ago
+31.56%
PainReform shares are trading higher after the com...
Unlock content with
Pro Subscription
1 month ago
-28.57%
PainReform shares are trading lower. The company announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
